EUCTR2017-000846-23-GB进行中（未招募）1 期
Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan® 0.01% in ocular hypertensive or glaucomatous patients. - In-SIGHT study
aboratoires THEA0 个研究点目标入组 668 人开始时间: 2018年7月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 668
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •At Screening Visit (D-42):
- •-Informed consent signed and dated.
- •-Patient aged =18 years old.
- •-Both eyes with 500 µm = central corneal thickness = 600 µm.
- •-Both eyes with diagnosed open-angle glaucoma or ocular hypertension, initially treated and controlled (including IOP = 18 mmHg) for at least 6 months by any prostaglandin monotherapy.
- •-Both eyes with IOP = 18 mmHg.
- •At Randomisation Visit (D1) at 8:00:
- •-Both eyes with 22 mmHg = IOP < 34 mmHg and with asymmetry between eyes = 3 mmHg.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 247
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 421
排除标准
- •Ophthalmic Exclusion Criteria in AT LEAST ONE EYE:
- •-Fundus examination not performed or not available within 12
- •-Visual field not performed or not available within 12 months.
- •- Significant worsening according to the two last visual fields (at
- •least 6 months between the two visual fields).
- •-Advance stage of glaucoma, defined by at least one of the following criteria:
- •- Absolute defect in the ten degrees central point of the visual field.
- •- Severe visual field loss: MD < -18 dB.
- •-Risk of visual field worsening as a consequence of participation in the study according to the investigator’s best judgement.
- •-History of non-responder to bimatoprost therapy.
- •-Far Best Corrected Visual Acuity = + 0.7 Log Mar (e.g., = 0.2 in decimal value or = 20/100 Snellen equivalent or = 50 ETDRS letters).
- •-History of trauma, infection, clinically significant inflammation
- •within the 3 previous months.
- •-Ongoing or known history of ocular allergy and/or uveitis
- •and/or viral infection.
- •-Clinically significant or progressive retinal disease (e.g. retinal
- •degeneration, diabetic retinopathy, retinal detachment).
- •-Presence of at least one severe objective sign among the following:
- •-Conjunctival hyperaemia (Grade 5 / McMonnies
- •-Superficial punctate keratitis (Grade 4/5 / Oxford
- •- Blepharitis (Grade 3 / 0-3 scale).
- •- Severe dry eye as assessed by the investigator.
- •- Corneal ulceration.
- •-Any palpebral abnormality incompatible with a good
- •examination.
- •-Any other abnormality preventing accurate assessment e.g. reliable tonometry measurement, visual field examination, fundus examination.
- •Regarding Systemic/non Ophthalmic Exclusion Criteria, Specific Exclusion Criteria Regarding Childbearing Potential Women, Exclusion Criteria Related to General Conditions and Exclusion Criteria Related to Previous and Concomitant Treatments (Medications/Non-Medicinal Therapies/Procedures) please refer to the study protocol in page 28.
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety assessment of T4032 versus Lumigan® in ocular hypertensive or glaucomatous patients.glaucoma, ocular hypertensionMedDRA version: 20.0Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2017-000846-23-ITABORATOIRES THEA434
进行中（未招募）
1 期
Efficacy and safety assessment of T4032 versus Lumigan® in ocular hypertensive or glaucomatous patients.EUCTR2017-000846-23-LVaboratoires THEA434
进行中（未招募）
1 期
Efficacy and safety assessment of T4032 versus Lumigan® in ocular hypertensive or glaucomatous patients.glaucoma, ocular hypertensionMedDRA version: 20.0Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2017-000846-23-LTaboratoires THEA668
进行中（未招募）
1 期
Efficacy and safety assessment of T4032 versus Lumigan® in ocular hypertensive or glaucomatous patients.glaucoma, ocular hypertensionMedDRA version: 20.0Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2017-000846-23-BGaboratoires THEA668
进行中（未招募）
1 期
Efficacy and safety assessment of T4032 versus Lumigan® in ocular hypertensive or glaucomatous patients.glaucoma, ocular hypertensionMedDRA version: 20.0Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2017-000846-23-FRaboratoires THEA434